Bryostatin-1: A Novel PKC Inhibitor in Clinical Development

References

• Jarvis W. D., Grant S. Protein kinase C targeting in antineoplastic treatment strategies. Invest. New Drugs 1999; 17: 227–240
   PubMed Web of Science ®Google Scholar
• Mellor H. P.P. The extended protein kinase C superfamily. Biochem. J. 1998; 332: 281–292
   PubMed Web of Science ®Google Scholar
• Cartee L., Davis C., Lin P. S., Grant S. Chronic exposure to bryostatin-1 increases the radiosensitivity of U937 leukaemia cells ectopically expressing Bcl-2 through a non-apoptotic mechanism. Int. J. Radiat. Biol. 2000; 76: 1323–1333
   PubMed Web of Science ®Google Scholar
• Mutter R., Wills M. Chemistry and clinical biology of the bryostatin-1s. Bioorg. Med. Chem. 2000; 8: 1841–1860
   PubMed Web of Science ®Google Scholar
• Wender P. A., Cribbs C. M., Koehler K. F., Sharkey N. A., Herald C. L., Kamano Y., Pettit G. R., Blumberg P. M. Modeling of the bryostatin-1s to the phorbol ester pharmacophore on protein kinase C. Proc. Natl. Acad. Sci. U. S. A. 1988; 85: 7197–7201
   PubMed Web of Science ®Google Scholar
• Kraft A. S., Smith J. B., Berkow R. L. Bryostatin-1, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc. Natl. Acad. Sci. U. S. A. 1986; 83: 1334–1338
   PubMed Web of Science ®Google Scholar
• de Vries D. J., Herald C. L., Pettit G. R., Blumberg P. M. Demonstration of sub nanomolar affinity of bryostatin-1 for the phorbol ester receptor in rat brain. Biochem. Pharmacol. 1988; 37: 4069–4073
   PubMed Web of Science ®Google Scholar
• Hennings H., Blumberg P. M., Pettit G. R., Herald C. L., Shores R., Yuspa S. H. Bryostatin-1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis 1987; 8: 1343–1346
   PubMed Web of Science ®Google Scholar
• Isakov N., Galron D., Mustelin T., Pettit G. R., Altman A. Inhibition of phorbol ester-induced T cell proliferation by bryostatin-1 is associated with rapid degradation of protein kinase C. J. Immunol. 1993; 150: 1195–1204
   PubMed Web of Science ®Google Scholar
• Lee H. W., Smith L., Pettit G. R., Vinitsky A., Smith J. B. Ubiquitination of protein kinase C-alpha and degradation by the proteasome. J. Biol. Chem. 1996; 271: 20973–20976
   PubMed Web of Science ®Google Scholar
• Hu Z. B., Ma W., Uphoff C. C., Lanotte M., Drexler H. G. Modulation of gene expression in the acute promyelocytic leukemia cell line NB4. Leukemia 1993; 7: 1817–1823
   PubMed Web of Science ®Google Scholar
• Song X., Sheppard H. M., Norman A. W., Liu X. Mitogen-activated protein kinase is involved in the degradation of p53 protein in the bryostatin-1-induced differentiation of the acute promyelocytic leukemia NB4 cell line. J. Biol. Chem. 1999; 274: 1677–1682
   PubMed Web of Science ®Google Scholar
• al-Katib A., Mohammad R. M., Khan K., Dan M. E., Pettit G. R., Sensenbrenner L. L. Bryostatin-1-induced modulation of the acute lymphoblastic leukemia cell line Reh. J. Immunother. 1993; 14: 33–42
   Web of Science ®Google Scholar
• Lilly M., Tompkins C., Brown C., Pettit G., Kraft A. Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin-1. Cancer Res. 1990; 50: 5520–5525
   PubMed Web of Science ®Google Scholar
• Li Y., Mohammad R. M., al-Katib A., Varterasian M. L., Chen B. Bryostatin-1 (bryo1)-induced monocytic differentiation in THP-1 human leukemia cells is associated with enhanced c-fyn tyrosine kinase and M- CSF receptors. Leuk. Res. 1997; 21: 391–397
   PubMed Web of Science ®Google Scholar
• Hu Z. B., Ma W., Uphoff C. C., Quentmeier H., Drexler H. G. C-kit expression in human megakaryoblastic leukemia cell lines. Blood 1994; 83: 2133–2444
   PubMed Web of Science ®Google Scholar
• Mohammad R. M., Maki A., Pettit G. R., al-Katib A. M. Bryostatin-1 induces ubiquitin COOH-terminal hydrolase in acute lymphoblastic leukemia cells. Enzyme Protein 1996; 49: 262–272
   PubMedGoogle Scholar
• al-Katib A., Mohammad R. M., Dan M., Hussein M. E., Akhtar A., Pettit G. R., Sensenbrenner L. L. Bryostatin-1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Exp. Hematol. 1993; 21: 61–65
   PubMed Web of Science ®Google Scholar
• al-Katib A., Mohammad R. M., Mohamed A. N., Pettit G. R., Sensenbrenner L. L. Conversion of high grade lymphoma tumor cell line to intermediate grade with TPA and bryostatin-1 as determined by polypeptide analysis on 2D gel electrophoresis. Hematol. Oncol. 1990; 8: 81–89
   PubMed Web of Science ®Google Scholar
• Mohammad R. M., Hamdan M. Y., al-Katib A. Induced expression of alpha-enolase in differentiated diffuse large cell lymphoma. Enzyme Protein 1994; 48: 37–44
   PubMedGoogle Scholar
• Hocevar B. A., Fields A. P. Selective translocation of beta II-protein kinase C to the nucleus of human promyelocytic (HL60) leukemia cells. J. Biol. Chem. 1991; 266: 28–33
   PubMed Web of Science ®Google Scholar
• Fields A. P., Pettit G. R., May W. S. Phosphorylation of lamin B at the nuclear membrane by activated protein kinase C. J. Biol. Chem. 1988; 263: 8253–8260
   PubMed Web of Science ®Google Scholar
• Kraft A. S., Baker V. V., May W. S. Bryostatin-1 induces changes in protein kinase C location and activity without altering c-myc gene expression in human promyelocytic leukemia cells (HL-60). Oncogene 1987; 1: 111–118
   PubMed Web of Science ®Google Scholar
• Drexler H. G., Gignac S. M., Jones R. A., Scott C. S., Pettit G. R., Hoffbrand A. V. Bryostatin-1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood 1989; 74: 1747–1757
   PubMed Web of Science ®Google Scholar
• May W. S., Tyler P. G., Ito T., Armstrong D. K., Qatsha K. A., Davidson N. E. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. J. Biol. Chem. 1994; 269: 26865–26870
   PubMed Web of Science ®Google Scholar
• Ruvolo P. P., Deng X., Carr B. K., May W. S. A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J. Biol. Chem. 1998; 273: 25436–25442
   PubMed Web of Science ®Google Scholar
• Kitada S., Zapata J. M., Andreeff M., Reed J. C. Bryostatin-1 and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 1999; 106: 995–1004
   PubMed Web of Science ®Google Scholar
• Wall N. R., Mohammad R. M., Reddy K. B., Al-Katib A. M. Bryostatin-1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line Reh. Int. J. Mol. Med. 2000; 5: 165–171
   PubMed Web of Science ®Google Scholar
• Vrana J. A., Wang Z., Rao A. S., Tang L., Chen J. H., Kramer L. B., Grant S. Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin-1. Leukemia 1999; 13: 1046–1055
   PubMed Web of Science ®Google Scholar
• Mohammad R. M., Diwakaran H., Maki A., Emara M. A., Pettit G. R., Redman B., al-Katib A. Bryostatin-1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk. Res. 1995; 19: 667–673
   PubMed Web of Science ®Google Scholar
• Wang H., Mohammad R. M., Werdell J., Shekhar P. V. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin-1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity. Int. J. Mol. Med. 1998; 1: 915–923
   PubMed Web of Science ®Google Scholar
• Wang S., Wang Z., Boise L. H., Dent P., Grant S. Bryostatin-1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL. Leukemia 1999; 13: 1564–1573
   PubMed Web of Science ®Google Scholar
• Wang S., Guo C. Y., Castillo A., Dent P., Grant S. Effect of bryostatin-1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Biochem. Pharmacol. 1998; 56: 635–644
   PubMed Web of Science ®Google Scholar
• Gschwend J. E., Fair W. R., Powell C. T. Bryostatin-1 induces prolonged activation of extracellular regulated protein kinases in and apoptosis of LNCaP human prostate cancer cells overexpressing protein kinase calpha. Mol. Pharmacol. 2000; 57: 1224–1234
   PubMed Web of Science ®Google Scholar
• Gomez-Angelats M., Bortner C. D., Cidlowski J. A. Protein kinase C (PKC) inhibits fas receptor-induced apoptosis through modulation of the loss of K + and cell shrinkage. A role for PKC upstream of caspases. J. Biol. Chem. 2000; 275: 19609–19619
   PubMed Web of Science ®Google Scholar
• Basu A., Akkaraju G. R. Regulation of caspase activation and cis-diamminedichloroplatinum(II)- induced cell death by protein kinase C. Biochemistry 1999; 38: 4245–4251
   PubMed Web of Science ®Google Scholar
• Haussermann S., Kittstein W., Rincke G., Johannes F. J., Marks F., Gschwendt M. Proteolytic cleavage of protein kinase Cmu upon induction of apoptosis in U937 cells. FEBS Lett. 1999; 462: 442–446
   PubMed Web of Science ®Google Scholar
• Wall N. R., Mohammad R. M., Nabha S. M., Pettit G. R., Al-Katib A. M. Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin-1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh. Biochem. Biophys. Res. Commun. 1999; 266: 76–80
   PubMed Web of Science ®Google Scholar
• Asiedu C., Biggs J., Lilly M., Kraft A. S. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin-1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res. 1995; 55: 3716–3720
   PubMed Web of Science ®Google Scholar
• Vrana J. A., Saunders A. M., Chellappan S. P., Grant S. Divergent effects of bryostatin-1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937). Differentiation 1998; 63: 33–42
   PubMed Web of Science ®Google Scholar
• Vrana J. A., Kramer L. B., Saunders A. M., Zhang X. F., Dent P., Povirk L. F., Grant S. Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells: relationship to apoptosis and differentiation. Biochem. Pharmacol. 1999; 58: 121–131
   PubMed Web of Science ®Google Scholar
• Koutcher J. A., Motwani M., Zakian K. L., Li X. K., Matei C., Dyke J. P., Ballon D., Yoo H. H., Schwartz G. K. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, blood flow. Clin. Cancer Res. 2000; 6: 1498–1507
   PubMed Web of Science ®Google Scholar
• Johnson M. D., Torri J. A., Lippman M. E., Dickson R. B. Regulation of motility and protease expression in PKC-mediated induction of MCF-7 breast cancer cell invasiveness. Exp. Cell Res. 1999; 247: 105–113
   PubMed Web of Science ®Google Scholar
• Wojtowicz-Praga S. M., Dickson R. B., Hawkins M. J. Matrix metalloproteinase inhibitors. Invest. New Drugs 1997; 15: 61–75
   PubMed Web of Science ®Google Scholar
• Al-Katib A. M., Smith M. R., Kamanda W. S., Pettit G. R., Hamdan M., Mohamed A. N., Chelladurai B., Mohammad R. M. Bryostatin-1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin. Cancer Res. 1998; 4: 1305–1314
   PubMed Web of Science ®Google Scholar
• Scala S., Dickstein B., Regis J., Szallasi Z., Blumberg P. M., Bates S. E. Bryostatin-1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells. Clin. Cancer Res. 1995; 1: 1581–1587
   PubMed Web of Science ®Google Scholar
• Puente L. G.S.J., Ostergaard H. L. Evidence for protein kinase C-dependent and -independent activation of mitogen-activated protein kinase in T cells: potential role of additional diacylglycerol binding proteins. J. Immunol. 2000; 165: 6865–6871
   PubMed Web of Science ®Google Scholar
• Kos F. J., Cornell D. L., Lipke A. B., Graham L. J., Bear H. D. Protective role of IL-2 during activation of T cells with bryostatin-1. Int. J. Immunopharmacol. 2000; 22: 645–652
   PubMed Web of Science ®Google Scholar
• Trenn G., Pettit G. R., Takayama H., Hu-Li J., Sitkovsky M. V. Immunomodulating properties of a novel series of protein kinase C activators. The bryostatin-1s. J. Immunol. 1988; 140: 433–439
   PubMed Web of Science ®Google Scholar
• Bosco M. C., Rottschafer S., Taylor L. S., Ortaldo J. R., Longo D. L., Espinoza-Delgado I. The antineoplastic agent bryostatin-1 induces proinflammatory cytokine production in human monocytes: synergy with interleukin-2 and modulation of interleukin-2Rgamma chain expression. Blood 1997; 89: 3402–3411
   PubMed Web of Science ®Google Scholar
• Lilly M., Brown C., Pettit G., Kraft A. Bryostatin-1: a potential anti-leukemic agent for chronic myelomonocytic leukemia. Leukemia 1991; 5: 283–287
   PubMed Web of Science ®Google Scholar
• Berkow R. L., Schlabach L., Dodson R., Benjamin W. H., Jr., Pettit G. R., Rustagi P., Kraft A. S. In vivo administration of the anticancer agent bryostatin-1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res. 1993; 53: 2810–2815
   PubMed Web of Science ®Google Scholar
• Szallasi Z., Du L., Levine R., Lewin N. E., Nguyen P. N., Williams M. D., Pettit G. R., Blumberg P. M. The bryostatin-1s inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin-1. Cancer Res. 1996; 56: 2105–2111
   PubMed Web of Science ®Google Scholar
• Schuchter L. M., Esa A. H., May S., Laulis M. K., Pettit G. R., Hess A. D. Successful treatment of murine melanoma with bryostatin-1. Cancer Res. 1991; 51: 682–687
   PubMed Web of Science ®Google Scholar
• Hornung R. L., Pearson J. W., Beckwith M., Longo D. L. Preclinical evaluation of bryostatin-1 as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res. 1992; 52: 101–107
   PubMed Web of Science ®Google Scholar
• Stanwell C., Gescher A., Bradshaw T. D., Pettit G. R. The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin-1 in human A549 lung and MCF-7 breast carcinoma cells. Int. J. Cancer. 1994; 56: 585–592
   PubMed Web of Science ®Google Scholar
• Hess A. D., Silanskis M. K., Esa A. H., Pettit G. R., May W. S. Activation of human T lymphocytes by bryostatin-1. J. Immunol. 1988; 141: 3263–3269
   PubMed Web of Science ®Google Scholar
• Kennedy M. J., Prestigiacomo L. J., Tyler G., May W. S., Davidson N. E. Differential effects of bryostatin-1 and phorbol ester on human breast cancer cell lines. Cancer Res. 1992; 52: 1278–1283
   PubMed Web of Science ®Google Scholar
• Dale I. L., Gescher A. Effects of activators of protein kinase C, including bryostatin-1s 1 and 2, on the growth of A549 human lung carcinoma cells. Int. J. Cancer. 1989; 43: 158–163
   PubMed Web of Science ®Google Scholar
• Mohammad R. M., Dugan M. C., Mohamed A. N., Almatchy V. P., Flake T. M., Dergham S. T., Shields A. F., Al-Katib A. A., Vaitkevicius V. K., Sarkar F. H. Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents. Pancreas 1998; 16: 19–25
   PubMed Web of Science ®Google Scholar
• Bodily J. M., Hoopes D. J., Roeder B. L., Gilbert S. G., Pettit G. R., Herald C. L., Rollins D. N., Robison R. A. The inhibitory effects of bryostatin-1 administration on the growth of rabbit papillomas. Cancer Lett. 1999; 136: 67–74
   PubMed Web of Science ®Google Scholar
• La Porta C. A., Di Dio A., Porro D., Comolli R. Overexpression of novel protein kinase C delta in BL6 murine melanoma cells inhibits the proliferative capacity in vitro but enhances the metastatic potential in vivo. Melanoma Res. 2000; 10: 93–102
   PubMed Web of Science ®Google Scholar
• McBain J. A., Pettit G. R., Mueller G. C. Phorbol esters activate proteoglycan metabolism in human colon cancer cells en route to terminal differentiation. Cell Growth Differ. 1990; 1: 281–291
   PubMedGoogle Scholar
• Jones R. J., Sharkis S. J., Miller C. B., Rowinsky E. K., Burke P. J., May W. S. Bryostatin-1, a unique biologic response modifier: anti-leukemic activity in vitro. Blood 1990; 75: 1319–1323
   PubMed Web of Science ®Google Scholar
• Mohammad R. M., al-Katib A., Pettit G. R., Sensenbrenner L. L. Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res. 1994; 54: 165–168
   PubMed Web of Science ®Google Scholar
• McGown A. T., Jayson G., Pettit G. R., Haran M. S., Ward T. H., Crowther D. Bryostatin-1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro. Br. J. Cancer. 1998; 77: 216–220
   PubMed Web of Science ®Google Scholar
• Mohammad R. M., Varterasian M. L., Almatchy V. P., Hannoudi G. N., Pettit G. R., Al-Katib A. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin-1. Clin. Cancer Res. 1998; 4: 1337–1343
   PubMed Web of Science ®Google Scholar
• Mohammad R. M., Wall N. R., Dutcher J. A., Al-Katib A. M. The addition of bryostatin-1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin. Cancer Res. 2000; 6: 4950–4956
   PubMed Web of Science ®Google Scholar
• Strum J. L.S.G., Pauig S. B., Daniel L. W. 1-[beta-d-arabinofuranosyl]cytosine stimulates ceramide and diglyceride formation in HL-60 cells. J. Biol. Chem. 1994; 269: 15493–15497
   PubMed Web of Science ®Google Scholar
• Grant S., Jarvis W. D., Turner A. J., Wallace H. J., Pettit G. R. Effects of bryostatin-1 and rGM-CSF on the metabolism of 1-beta-d-arabinofuranosylcytosine in human leukaemic myeloblasts. Br. J. Haematol. 1992; 82: 522–528
   PubMed Web of Science ®Google Scholar
• Elgie A. W., Sargent J. M., Alton P., Peters G. J., Noordhuis P., Williamson C. J., Taylor C. G. Modulation of resistance to ara-C by bryostatin-1 in fresh blast cells from patients with AML. Leuk. Res. 1998; 22: 373–378
   PubMed Web of Science ®Google Scholar
• Grant S., Boise L., Westin E., Howe C., Pettit G. R., Turner A., McCrady C. In vitro effects of bryostatin-1 on the metabolism and cytotoxicity of 1-beta-d-arabinofuranosylcytosine in human leukemia cells. Biochem. Pharmacol. 1991; 42: 853–867
   PubMed Web of Science ®Google Scholar
• Jarvis W. D., Povirk L. F., Turner A. J., Traylor R. S., Gewirtz D. A., Pettit G. R., Grant S. Effects of bryostatin-1 and other pharmacological activators of protein kinase C on 1-[beta-d-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem. Pharmacol. 1994; 47: 839–852
   PubMed Web of Science ®Google Scholar
• Liu K. Z., Schultz C. P., Johnston J. B., Beck F. W., Al-Katib A. M., Mohammad R. M., Mantsch H. H. Infrared spectroscopic study of bryostatin-1-induced membrane alterations in a B-CLL cell line. Leukemia 1999; 13: 1273–1280
   PubMed Web of Science ®Google Scholar
• Beck F. W., Al-Katib A. M., Ahmad I., Wall N. R., Liu K. Z., Mantsch H. H., Mohammad R. M. Bryostatin-1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells. Int. J. Mol. Med. 2000; 5: 341–347
   PubMed Web of Science ®Google Scholar
• Mohammad R. M., Beck F. W., Katato K., Hamdy N., Wall N., al-Katib A. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin-1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5′-NT and Bax/Bcl-2. Biol. Chem. 1998; 379: 1253–1261
   PubMed Web of Science ®Google Scholar
• Mohammad R. M., Limvarapuss C., Hamdy N., Dutcher B. S., Beck F. W., Wall N. R., Al-Katib A. M. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin-1 followed by fludarabine. Int. J. Oncol. 1999; 14: 945–950
   PubMed Web of Science ®Google Scholar
• Kaubisch A. K.D., Saltz L., et al. Phase I trial of weekly sequential bryostatin-1 (Bryo), cisplatin, and paclitaxel in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 2000; 19: 230a
   Google Scholar
• Hickman P. F., Kemp G. J., Thompson C. H., Salisbury A. J., Wade K., Harris A. L., Radda G. K. Bryostatin-1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study. Br. J. Cancer 1995; 72: 998–1003
   PubMed Web of Science ®Google Scholar
• Prendiville J., Crowther D., Thatcher N., Woll P. J., Fox B. W., McGown A., Testa N., Stern P., McDermott R., Potter M., et al. A phase I study of intravenous bryostatin-1 in patients with advanced cancer. Br. J. Cancer 1993; 68: 418–424
   PubMed Web of Science ®Google Scholar
• Cheung A. P., Hallock Y. F., Vishnuvajjala B. R., Nguyenle T., Wang E. Compatibility and stability of bryostatin-1 in infusion devices. Invest. New Drugs 1998; 16: 227–236
   PubMed Web of Science ®Google Scholar
• Jayson G. C., Crowther D., Prendiville J., McGown A. T., Scheid C., Stern P., Young R., Brenchley P., Chang J., Owens S., et al. A phase I trial of bryostatin-1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br. J. Cancer 1995; 72: 461–468
   PubMed Web of Science ®Google Scholar
• Philip P. A., Rea D., Thavasu P., Carmichael J., Stuart N. S., Rockett H., Talbot D. C., Ganesan T., Pettit G. R., Balkwill F., et al. Phase I study of bryostatin-1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J. Natl. Cancer Inst. 1993; 85: 1812–1818
   PubMed Web of Science ®Google Scholar
• Varterasian M. L., Mohammad R. M., Eilender D. S., Hulburd K., Rodriguez D. H., Pemberton P. A., Pluda J. M., Dan M. D., Pettit G. R., Chen B. D., Al-Katib A. M. Phase I study of bryostatin-1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J. Clin. Oncol. 1998; 16: 56–62
   PubMed Web of Science ®Google Scholar
• Marshall J. I.J.M., Rizvi N., et al. Phase I trial of prolonged infusion bryostatin-1 in patients with advanced cancer. Proc. Am. Assoc. Cancer Res. 1998; 39: 601
   Google Scholar
• Langevin A. M.B.M., Kraft A. S., et al. Phase I trial of bryostatin-1 in childhood solid tumors: a Pediatric Oncology Group (POG) study. Proc. Am. Soc. Clin. Oncol. 1998; 17: 206
   Google Scholar
• Weitman S., Langevin A. M., Berkow R. L., Thomas P. J., Hurwitz C. A., Kraft A. S., Dubowy R. L., Smith D. L., Bernstein M. A phase I trial of bryostatin-1 in children with refractory solid tumors: a pediatric oncology group study. Clin. Cancer Res. 1999; 5: 2344–2348
   PubMed Web of Science ®Google Scholar
• Institute N. C. Drug products, bryostatin-1 (NSC 339555). Fact Sheet April 1, 1997
   Google Scholar
• Grant S., Roberts J., Poplin E., Tombes M. B., Kyle B., Welch D., Carr M., Bear H. D. Phase Ib trial of bryostatin-1 in patients with refractory malignancies. Clin. Cancer Res. 1998; 4: 611–618
   PubMed Web of Science ®Google Scholar
• Pavlick A. C.H.A., Liebes L., et al. Bryostatin-1 and Cisplatin: a phase I and pharmacodynamic study. Proc. Am. Soc. Clin. Oncol. 2001; 20: a328
   Google Scholar
• Bangalore N. S.B.S., Bhargava P., et al. Phase I study of bryostatin-1 and cisplatin in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 2000; 19, a794,204a
   Web of Science ®Google Scholar
• Lenz H. J.G.M., Xiong Y. P., et al. Phase I study of bryostatin-1 and cisplatin (CDDP). Proc. Am. Soc. Clin. Oncol. 2000; 19, a795, 204a
   Google Scholar
• Dowlati A. R.K., Ksenich P., et al. Phase I trial of combination of bryostatin-1 and vincristine in B-cell malignancies. Proc. Am. Soc. Clin. Oncol. 2000; 19, a837,215a
   Google Scholar
• Grant S. C.L., Smith M. B., et al. Phase I trial of the signal transduction modulator bryostatin-1 (NSC 399555) and fludarabine in patients with progressive CLL and refractory indolent non-Hodgkin's lymphoma. Blood 2000; 93 Supplement 1: a590
   Google Scholar
• Propper D. J., Macaulay V., O'Byrne K. J., Braybrooke J. P., Wilner S. M., Ganesan T. S., Talbot D. C., Harris A. L. A phase II study of bryostatin-1 in metastatic malignant melanoma. Br. J. Cancer. 1998; 78: 1337–1341
   PubMed Web of Science ®Google Scholar
• Gonzalez R., Ebbinghaus S., Henthorn T. K., Miller D., Kraft A. S. Treatment of patients with metastatic melanoma with bryostatin-1—a phase II study. Melanoma Res. 1999; 9: 599–606
   PubMed Web of Science ®Google Scholar
• Bedikian A. Y., Plager C., Stewart J. R., O'Brian C. A., Herdman S. K., Ross M., Papadopoulos N., Eton O., Ellerhorst J., Smith T. Phase II evaluation of bryostatin-1 in metastatic melanoma. Melanoma Res. 2001; 11: 183–188
   PubMed Web of Science ®Google Scholar
• Pagliaro L., Daliani D., Amato R., Tu S. M., Jones D., Smith T., Logothetis C., Millikan R. A phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer 2000; 89: 615–618
   PubMed Web of Science ®Google Scholar
• Zonder J. A., Shields A. F., Zalupski M., Chaplen R., Heilbrun L. K., Arlauskas P., Philip P. A. A phase II trial of bryostatin-1 in the treatment of metastatic colorectal cancer. Clin. Cancer Res. 2001; 7: 38–42
   PubMed Web of Science ®Google Scholar
• Blackhall F. H., Ranson M., Radford J. A., Hancock B. W., Soukop M., McGown A. T., Robbins A., Halbert G., Jayson G. C. A phase II trial of bryostatin-1 in patients with non-Hodgkin's lymphoma. Br. J. Cancer 2001; 84: 465–469
   PubMed Web of Science ®Google Scholar
• Brockstein B., Samuels B., Humerickhouse R., Arietta R., Fishkin P., Wade J., Sosman J., Vokes E. E. Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer. Invest. New Drugs 2001; 19: 249–254
   PubMed Web of Science ®Google Scholar
• Varterasian M. L., Mohammad R. M., Shurafa M. S., Hulburd K., Pemberton P. A., Rodriguez D. H., Spadoni V., Eilender D. S., Murgo A., Wall N., Dan M., Al-Katib A. M. Phase II trial of bryostatin-1 in patients with relapsed low-grade non- Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin. Cancer Res. 2000; 6: 825–828
   PubMed Web of Science ®Google Scholar
• Ilson D. S.M., O'reilly E., Kelsen D., Welch M., Kaubisch A., Schwartz G. K. A phase II trial of weekly one-hour paclitaxel followed by bryostatin-1 in patients with advanced esophageal cancer: an active new drug combination. Proc. Am. Soc. Clin. Oncol. 2001; 20: a633,159
   Google Scholar
• Charoentum C. M.A., Gajewski T. F., et al. Phase II study of bryostatin-1 in combination with paclitaxel for advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 2001; 20: a2834
   Google Scholar
• Tuttle T. M., Inge T. H., Bethke K. P., McCrady C. W., Pettit G. R., Bear H. D. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin-1. Cancer Res. 1992; 52: 548–553
   PubMed Web of Science ®Google Scholar
• Tuttle T. M., Bethke K. P., Inge T. H., McCrady C. W., Pettit G. R., Bear H. D. Bryostatin-1-activated T cells can traffic and mediate tumor regression. J. Surg. Res. 1992; 52: 543–548
   PubMed Web of Science ®Google Scholar
• Tuttle T. M., Inge T. H., Lind D. S., Bear H. D. Adoptive transfer of bryostatin-1-activated T cells provides long-term protection from tumour metastases. Surg. Oncol. 1992; 1: 299–307
   PubMedGoogle Scholar
• Tuttle T. M., McCrady C. W., Inge T. H., Salour M., Bear H. D. Gamma-interferon plays a key role in T-cell-induced tumor regression. Cancer Res. 1993; 53: 833–839
   PubMed Web of Science ®Google Scholar
• Tuttle T. M., Inge T. H., Wirt C. P., Frank J. L., McCrady C. M., Bear H. D. Bryostatin-1 activates T cells that have antitumor activity. J. Immunother. 1992; 12: 75–81
   PubMed Web of Science ®Google Scholar
• Baldwin N. G., Rice C. D., Tuttle T. M., Bear H. D., Hirsch J. I., Merchant R. E. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes. J. Neurooncol. 1997; 32: 19–28
   PubMed Web of Science ®Google Scholar
• Rice C. D., Baldwin N. G., Biron R. T., Bear H. D., Merchant R. E. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes. J. Neurooncol. 1997; 32: 29–38
   PubMed Web of Science ®Google Scholar
• Chin C. S., Graham L. J., Hamad G. G., George K. R., Bear H. D. Bryostatin-1/ionomycin-activated T cells mediate regression of established tumors. J. Surg. Res. 2001; 98: 108–115
   PubMed Web of Science ®Google Scholar
• Fleming M. D., Bear H. D., Lipshy K., Kostuchenko P. J., Portocarero D., McFadden A. W., Barrett S. K. Adoptive transfer of bryostatin-1-activated tumor-sensitized lymphocytes prevents or destroys tumor metastases without expansion in vitro. J. Immunother. Emphas. Immunol. 1995; 18: 147–155
   PubMed Web of Science ®Google Scholar
• Lind D. S., Tuttle T. M., Bethke K. P., Frank J. L., McCrady C. W., Bear H. D. Expansion and tumour specific cytokine secretion of bryostatin-1-activated T-cells from cryopreserved axillary lymph nodes of breast cancer patients. Surg. Oncol. 1993; 2: 273–282
   PubMed Web of Science ®Google Scholar
• Bear H. D., Roberts J., Cornell D., Tombes M. B., Kyle B. Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial. Cancer Immunol. Immunother. 2001; 50: 269–274
   PubMed Web of Science ®Google Scholar
• van der Hem K. G., Drager A. M., Odding J. H., Langenhuijsen M. M., Huijgens P. C. Bryostatin-1-5 stimulates normal human hematopoiesis and inhibits proliferation of HL60 leukemic cells. Leuk. Res. 1995; 19: 7–13
   PubMed Web of Science ®Google Scholar
• van der Hem K. G., Drager A. M., Odding J. H., Huijgens P. C. Effects of bryostatin-1-5 and hematopoietic growth factors on acute myeloid leukemia cell differentiation, proliferation, and primary plating efficiency. Leuk. Res. 1995; 19: 651–657
   PubMed Web of Science ®Google Scholar
• Kraft A. S., Woodley S., Pettit G. R., Gao F., Coll J. C., Wagner F. Comparison of the antitumor activity of bryostatin-1s 1, 5, and 8. Cancer Chemother. Pharmacol. 1996; 37: 271–278
   PubMed Web of Science ®Google Scholar
• Bignami G. S., Wagner F., Grothaus P. G., Rustagi P., Davis D. E., Kraft A. S. Biological activity of 26-succinylbryostatin-1. Biochim. Biophys. Acta 1996; 1312: 197–206
   PubMed Web of Science ®Google Scholar